Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced it’s completed the construction of an mRNA drug substance production suite at its plant in Songdo, South Korea. The CDMO had already established drug product capabilities for mRNA vaccine production, providing fill/finish manufacturing, labeling, and packaging for Moderna’s COVID-19 mRNA vaccines. The addition of …